温肾止泻方敷脐对脾肾阳虚型IBS-D患者5-HT、NO含量的影响

张庆伟; 孟浩; 唐寅; 蔡丽霞; 李向; 李娜

温肾止泻方敷脐对脾肾阳虚型IBS-D患者5-HT、NO含量的影响

南京中医药大学附属张家港医院，江苏张家港 215600

计量
- 文章访问数: 894
- HTML全文浏览量: 2
- PDF下载量: 649
- 被引次数: 0
出版历程
- 刊出日期: 2016-05-10

Influence of Wenshen Zhixie Fang Administrated through Bellybutton on 5-HT and NO of Spleen and Kidney Yang Deficiency Type IBS-D Patients

摘要

摘要: 目的观察温肾止泻方敷脐治疗腹泻型肠易激综合征（IBS-D）脾肾阳虚型患者的临床疗效及其对5-HT、NO水平的影响。方法采用电脑随机、平行对照、非盲法试验将患者随机分为2组，试验组58例使用温肾止泻方敷脐配合口服蒙脱石散；对照组59例口服蒙脱石散，治疗10d后评价其疗效差异。结果试验组总有效率为82.76%，优于对照组的66.10%(P<0.05)；试验组能明显改善腹痛或不适、大便性状、大便次数等症状（P<0.01），除大便性状外，改善程度均优于对照组（P<0.01）；试验组能明显降低血清5-HT含量，升高NO含量，作用优于对照组（P<0.01）。结论温肾止泻方敷脐可以改善脾肾阳虚型IBS-D的临床症状，其作用机制可能是通过调节5-HT、NO水平，减轻肠道敏感性。
- 温肾止泻方 /
- 敷脐 /
- 腹泻型肠易激综合征
Abstract: OBJECTIVE To investigate the effects of Whenshen Zhixie Fang administrated through bellybutton and the influence on 5-HT and NO of spleen and kidney yang deficiency type IBS-D patients. METHODS By using computer， parallel group and non-blinded trials， patients were randomly divided into two groups. 58 cases in the treatment group were given Wenshen Zhixie Fang administrated through bellybutton together with orally taken Montmorillonite powder. The control group was given orally taken Montmorillonite powder only. The treating effects were assessed after ten days. RESULTS Total effective rate of the treatment group was 82.76%， which was better than that of the control group (66.10%)(P<0.05). Abdominal pain and discomfort were significantly relieved in the treatment group， and the shape of the stool and frequency were also changed for better (P<0.01)， which were better than those of the control group except the stool. And 5-HT was significantly decreased and NO was increased， which were better than those of the control group(P<0.01).CONCLUSION Wenshen Zhixie Fang administered through Bellybutton can improve the clinical symptoms of IBS-D and its mechanism may be related to the regulation of 5-HT and NO levels and reduction of intestinal sensitivity.
- Wenshen Zhixie Fang /
- administered through bellybutton /
- IBS-D

HTML全文

参考文献(8)

[1]	Bixquert M. Treatment of irritable bowel syndrome with probiotics: growing evidence[J]. Indian J Med Res， 2013， 138(2): 175-177.
[2]	罗马委员会.功能性胃肠病罗马Ⅲ诊断标准[J].胃肠病学，2006， 11（12）：761-765.
[3]	Roman Committee. Diagnostic criteria of Rome Ⅲ for functional gastrointestinal disorders[J]. Chin J Gastroenterol， 2006， 11(12):761-765.
[4]	中华中医药学会脾胃病分会.肠易激综合征中医诊疗共识意见[J]中华中医药杂志，2010，25(7):1062-1065.
[5]	The Spleen and Stomach Disease Branch of China Association of Chinese Medicine. Consensus on the diagnosis and treatment of irritable bowel syndrome by TCM[J]. Chin J Tradit Chin Med， 2010， 25(7):1062-1065.
[6]	中药新药临床研究指导原则：试行[M].北京：中国医药科技出版社，2002:139-143.
[7]	Clinical Guideline of New Drugs for Traditional Chinese Medicine[M]. Beijing: China medical science press，2002：139-143.
[8]	Mayer EA， Bradesi S. Alosetron and irritable bowel syndrome[J]. Expert Opin Pharmacother， 2003， 4(11): 2089-2098.